Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dityline-Biolik is a brand of suxamethonium iodide (succinylcholine iodide), a short-acting depolarizing neuromuscular blocker. It is developed and manufactured by Farmstandart-Biolik in Ukraine. Suxamethonium iodide acts as an agonist at the muscle-type nicotinic acetylcholine receptors at the neuromuscular junction, causing prolonged depolarization of the motor endplate. This leads to transient muscle fasciculations followed by flaccid skeletal muscle paralysis. It is approved for use as an adjunct to general anesthesia to facilitate endotracheal intubation, provide skeletal muscle relaxation during surgical procedures, and manage convulsions associated with tetanus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on suxamethonium iodide.